Drug Profile
Research programme: retinitis pigmentosa therapeutics - Asklepios
Alternative Names: BNP-RPLatest Information Update: 27 May 2021
Price :
$50
*
At a glance
- Originator Asklepios BioPharmaceutical
- Developer Asklepios BioPharmaceutical; ForSight VISION4
- Class Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Retinitis pigmentosa
Most Recent Events
- 10 Jan 2017 ForSight VISION4 has been acquired by and merged into Roche
- 16 Jul 2016 No recent reports of development identified for research development in Retinitis-pigmentosa in USA (Parenteral)
- 25 Sep 2012 Early research in Retinitis pigmentosa in USA (Parenteral)